Pivotal-Point Tracking Omeros (OMER): First FDA-Approved TA-TMA Therapy Yartemlea as a Monopoly Provider and Stock Driver

Omeros is a US biotechnology company that develops therapies for rare immune and complement disorders. On August 12, the company significantly exceeded market expectations in the second quarter with an adjusted profit of $0.02 per share and a net revenue of $28.5 million (expectation: $12.7 million). The main driver was the successful launch of the antibody Yartemlea for the treatment of complications from stem cell transplants. Additionally, the company achieved a positive operating cash flow of $4.1 million. Omeros benefits in two ways from the...